ACXP on Nasdaq
Acurx Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and Development | $1.8M | $5.4M |
| General and Administrative | $6.3M | $8.7M |
| TOTAL OPERATING EXPENSES | $8.1M | $14.1M |
| OPERATING LOSS | -$8.1M | -$14.1M |
| Interest Income | $125.4K | $20.1K |
| NET LOSS | -$8.0M | -$14.1M |
| Basic net loss per common share | -$5.32 | -$17.45 |
| Diluted net loss per common share | -$5.32 | -$17.45 |
| Weighted average common shares outstanding basic | 1.5M shares | 808.2K shares |
| Weighted average common shares outstanding diluted | 1.5M shares | 808.2K shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Cash | $7.6M | $3.7M | |
| Other Receivable | $48.4K | $51.1K | |
| Prepaid Expenses | $85.0K | $100.1K | |
| TOTAL ASSETS | $7.7M | $3.9M | |
| Accounts Payable and Accrued Expenses | $2.4M | $3.2M | |
| TOTAL CURRENT LIABILITIES | $2.4M | $3.2M | |
| TOTAL LIABILITIES | $2.4M | $3.2M | |
| Common Stock; $0.001 par value, 250,000,000 shares authorized, 2,348,113 shares issued and outstanding at December 31, 2025 and 200,000,000 shares authorized, 851,534 shares issued and outstanding at December 31, 2024 | $2.3K | $852 | |
| Additional Paid-In Capital | $80.6M | $67.9M | |
| Accumulated Deficit | -$75.3M | -$67.3M | |
| TOTAL SHAREHOLDERS' EQUITY | $5.3M | $615.1K | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $7.7M | $3.9M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred Stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 250.0M shares | 250.0M shares | 200.0M shares |
| Common stock, Issued (in shares) | 2.3M shares | 851.5K shares | |
| Common stock, outstanding (in shares) | 2.3M shares | 851.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$8.0M | -$14.1M |
| Share-Based Compensation | $1.2M | $2.6M |
| Share-Based Payments to Vendors | $322.3K | $833.7K |
| Other Receivable | $2.7K | $78.0K |
| Prepaid Expenses | $15.1K | $5.7K |
| Accounts Payable and Accrued Expenses | -$408.8K | $200.4K |
| Net Cash Used in Operating Activities | -$6.8M | -$10.4M |
| Reverse Stock Split fractional share adjustment | -$1.0K | |
| Proceeds from Warrant Inducement, net of issuance costs | $2.5M | |
| Proceeds from Warrant Exercise | $1.4M | $210.2K |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | $3.8M | |
| Proceeds from 2025 March Registered Direct Offering, net of issuance costs | $889.4K | |
| Proceeds from 2025 January Registered Direct Offering, net of issuance costs | $2.1M | |
| Proceeds from At-the-Market Offering, net of issuance costs | $6.4M | |
| Net Cash Provided by Financing Activities | $10.6M | $6.6M |
| Net Increase/(Decrease) in Cash | $3.8M | -$3.8M |
| Share-Based Compensation to settle accrued compensation (Note 5) | $413.1K | |
| 2025 Equity Line of Credit Purchase Agreement costs (Commitment shares)(Note 4) | $360.0K | |
| 2025 Warrant Inducement Financing costs (Note 4) | $4.6M |
Former names
- Acurx Pharmaceuticals, LLCApr 3, 2018 to Jun 23, 20212
Recent filings
- Sep 17, 2026424B3
- Sep 17, 2026EFFECT
- Sep 8, 2026S-1
- Sep 1, 2026DEF 14A
- Sep 1, 2026DEFA14A
- Sep 1, 2026ARS
- Aug 13, 202610-Q
- May 12, 2026424B3
- May 12, 2026424B3
- May 11, 202610-Q
- May 11, 2026EFFECT
- May 11, 2026EFFECT
- May 7, 2026UPLOAD
- May 7, 2026UPLOAD
- May 7, 2026CORRESP
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9